The cytosine analogues 5‐azacytosine (azacytidine) and 2′‐deoxy‐5‐azacytidine
(decitabine) are the currently most advanced drugs for epigenetic cancer therapies. These …

The DNA methyltransferase (DNMT) inhibitors azacytidine and decitabine are the most
successful epigenetic drugs to date and are still the most widely used as epigenetic …

Background DNA methylation is the addition of a methyl group to the 5 position of cytosine. It
is an epigenetic process with several effects, including chromatin structure modulation …

Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …

Methylation of DNA at 5-position of cytosine, catalyzed by DNA methyltransferases, is the
predominant epigenetic modification in mammals. Aberrations in methylation play a causal …

Epigenetic events, such as aberrant DNA methylation, have been demonstrated to silence
the expression of many genes that suppress malignancy. Since the event is reversible, it is …

Purpose The DNA methyltransferase inhibitor 5-aza-2-deoxycytidine (decitabine) induces
DNA demethylation and re-expression of epigenetically silenced genes, and increases …

Purpose The nucleoside analog 5-aza-2#-deoxycytidine (5-aza-CdR, decitabine) is a potent
inhibitor of DNA methylation in vitro. Cellular treatment with this agent induces the re …

Hypermethylation of tumor suppressor genes caused by aberrant activity of DNA
methyltransferases is an important mechanism that contributes to cancer. The reaction …

Azacytidine was first synthesized almost 40 years ago. It was demonstrated to have a wide
range of anti-metabolic activities when tested against cultured cancer cells and to be an …